Inactive Instrument

Press Releases Oxford BioMedica plc London S.E.

Equities

GB0006648157_GB

GB0006648157

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oxford Biomedica : Preliminary results for the year ended 31 December 2023 29 April 2024	Apr. 29	PU
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results	Mar. 05	AQ
Oxford Biomedica completes acquisition of ABL Europe	Jan. 29	AQ
Oxford Biomedica is hosting a free webinar to share Clients success stories in viral vector manufacturing	Jan. 24	AQ
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing	Jan. 23	AQ
Oxford Biomedica plc - Business Update	Dec. 08	AQ
Business Update	Dec. 07	AQ
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Merieux, consolidating position as a global pure-play CDMO	Dec. 05	AQ
Firm Oxford Biomedica snaps up ABL Europe	Dec. 05	AQ
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO	Dec. 04	AQ
Oxford Biomedica : Interim results for the year ended 30 June 202320 September 2023	23-10-16	PU
Oxford Biomedica : 2023 Interim report	23-10-03	PU
Oxford Biomedica and Institut Merieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Merieux as part of pure-play CDMO transformation	23-09-21	AQ
Oxford Biomedica plc - Director Dealings	23-09-21	AQ
Oxford Biomedica and Institut Merieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe	23-09-21	AQ
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector Platform	23-09-21	AQ
Oxford Biomedica PLC interim results for the six months ended 30 June 2023	23-09-21	AQ
Oxford Biomedica : 2023 interim results21 September 2023	23-09-20	PU
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation	23-09-20	AQ
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023	23-09-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oxford BioMedica plc London S.E.

Equities

GB0006648157_GB

GB0006648157

Press Releases

Filters